BAYRY
Get informed when a big investor buys or sells
+ FollowMarch 4, 2026 - AI Summary
Overvalued by 47.3% based on the discounted cash flow analysis.
| Market cap | $55.25 Billion |
|---|---|
| Enterprise Value | $90.79 Billion |
| Dividend Yield | $0.03 (0.23%) |
| Earnings per Share | $-0.88 |
| Beta | 0.83 |
| Outstanding Shares | 3,929,696,328 |
| P/E Ratio | -27.3 |
|---|---|
| PEG | 12.88 |
| Price to Sales | 1.18 |
| Price to Book Ratio | 2.02 |
| Enterprise Value to Revenue | 1.92 |
| Enterprise Value to EBIT | 16.96 |
| Enterprise Value to Net Income | -50 |
| Total Debt to Enterprise | 0.44 |
| Debt to Equity | 1.35 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Holdings and activity of institutional investors.
| Ownership % | 0.17%▼ 0.01% |
|---|---|
| Total Invested | $78.74M▲ 1.75% |
| Investors Holding | 16▼ 2.00% |
No data
Bayer AG engages in the development, manufacture and distribution of products in the areas of health care, nutrition and high-tech materials. It operates through the following segments: Pharmaceuticals, Consumer Health, Crop Science, Ani...